New York pharmaceutical company Pfizer Inc. (NYSE: PFE) has completed its purchase of specialty pharmaceutical company, NextWave Pharmaceuticals Inc. for as much as $700 million.

NextWave develops and commercializes products, including Quillivant XR, that treat attention deficit hyperactivity disorder.

The price includes a $255 million payment to shareholders, plus $425 in potential additional payments based on sales milestones.

The deal was announced Oct. 22

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.